Periostin in Inflammatory Bowel Disease (IBD) development and synergistic effects mediated via CCL5
Loading...
Date
2018-10-18
Authors
Riethmacher, Eva
Vangelista, Luca
Mukanova, Saida
Riethmacher, Dieter
Journal Title
Journal ISSN
Volume Title
Publisher
Nazarbayev University
Abstract
The incidence of IBD is rising all over the world and is affecting 1 in
4000 people in Europe and 1 in 16.000 in Asia. [1] Welldocumented,
reliable numbers for Kazakhstan are currently not
available but observations from local physicians (personal
communication) suggest that numbers might be significantly higher
than suggested by the literature. The matricellular protein Periostin
has recently been shown to be involved in IBD [2] (and our own
unpublished data). In a chemically induced murine model (dextrane
sulfate sodium DSS) it mediates intestinal inflammation through the
activation of NF-κB signaling, which suggests that periostin is a
potential therapeutic target for inflammatory bowel disease [2].
CCL5, also know as RANTES, is a chemokine shown to be
interacting with the G protein-coupled receptors CCR1, CCR3 and
CCR5 [3]. In a recent study it could be shown that CCR5 expression
correlates with the infiltration of inflammatory cells into the lamina
propria of IBD patients [4].
Periostin is a matricellular protein originally isolated from
osteoblasts and found to be preferentially expressed in the
periosteum [5, 6]. Periostin contains an N-terminal secretory signal
peptide, followed by a cysteine-rich domain, four internal
homologous repeats, and a C-terminal hydrophilic domain. The four
internal repeats exhibit homology to the axon guidance protein
fasciclin I that is involved in the development of nervous system in
invertebrates and were thus named fasciclin domains.
Description
Keywords
chemokine receptors (CCRs), INFLAMMATORY BOWEL DISEASE (IBD)
Citation
Riethmacher, Eva et al. (2018) Periostin in Inflammatory Bowel Disease (IBD) development and synergistic effects mediated via CCL5. Nazarbayev University